Conclusion:  Endoplasmic reticulum stress might be involved in lipogenesis in

fatty acids-induced hepatic steatosis. Talazoparib mouse Therefore, endoplasmic reticulum stress might serve as a novel target in the pathogenesis and therapy of non- alcoholic fatty liver disease. “
“Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med 2013;19:329-336. (Reprinted with permission.) Oncolytic viruses and active immunotherapeutics have complementary mechanisms of action (MOA) that are both self amplifying in tumors, yet the impact of dose on subject outcome is unclear. JX-594 (Pexa-Vec) is an oncolytic and immunotherapeutic vaccinia virus. To determine the optimal JX-594 dose in subjects with advanced hepatocellular carcinoma (HCC), we conducted a randomized phase 2 dose-finding trial (n = 30). Radiologists infused low- or high-dose JX-594 into liver tumors (days 1, 15 and 29); infusions resulted in acute detectable intravascular JX-594 genomes. Objective intrahepatic Modified Response Evaluation Criteria in Solid Tumors (mRECIST) (15%) and Choi (62%) response rates and intrahepatic disease control (50%) were Selleck Epigenetics Compound Library equivalent

in injected and distant noninjected tumors at both doses. JX-594 replication and granulocyte-macrophage colony-stimulating factor (GM-CSF) expression preceded the induction of anticancer immunity. In contrast to tumor response rate and immune endpoints, subject survival duration was significantly related to dose (median survival of 14.1 months compared to 6.7 months on the high and low dose, respectively;

hazard ratio 0.39; P = 0.020). JX-594 demonstrated oncolytic and immunotherapy MOA, tumor responses and dose-related survival in individuals with HCC. Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death in men and claims more than 700,000 lives per year worldwide.[1, 2] The age-adjusted incidence of HCC in the U.S. more than doubled within the past 35 years, and it is medchemexpress projected to continue to be the fastest-growing cancer in the U.S. for at least another 15 years. However, the prognosis remains dismal, with a 5-year survival rate slightly above 10%.[2] The risk factors for HCC can be divided into two major groups: (1) viral hepatitis, including chronic hepatitis B and chronic hepatitis C infection; and (2) chronic nonviral hepatic inflammation, such as alcoholic and nonalcoholic fatty liver disease, autoimmune hepatitis, and primary biliary cirrhosis. Approximately 85% of HCCs arise in livers with chronic hepatitis or cirrhosis. In clinical practice, cirrhosis is recognized as a high-risk preneoplastic condition and HCC surveillance with abdominal ultrasound every 6 months is recommended for all individuals with cirrhosis by both the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL).